Agreement for Large-Scale Genotyping Studies
News Sep 23, 2005
Illumina, Inc. has announced that it has signed a commercial, multi-year, genotyping services agreement with GlaxoSmithKline (GSK).
Under the terms of the agreement, Illumina will use Sentrix® Arrays in conjunction with the Company's GoldenGate® and Infinium™ assays to conduct genetic studies for thousands of samples provided by GSK.
The blanket agreement enables multiple projects to be conducted over period of time.
Illumina has worked directly with GSK since June 2001, genotyping samples for a number of pharmacogenomics studies.
Schizophrenics' Blood Contains RNA From More MicrobesNews
The blood of schizophrenia patients features genetic material from more types of microorganisms than that of people without the debilitating mental illness, research at Oregon State University has found. What’s not known is whether that’s a cause or effect of the severe, chronic condition that strikes about one person in 100.READ MORE
Faulty Gene Leads to Alcohol-Induced Heart FailureNews
A faulty gene interacts with alcohol to accelerate heart failure in susceptible patients, a study suggests. This dangerous interaction can occur even when only moderate amounts of alcohol have been consumed.READ MORE